Contribution: Industrial Research Assistance Program – Contributions to Firms
Kalgene Pharmaceuticals Inc.
$350,000.00
Development of a Biological Therapeutic Drug to Reverse Alzheimer's Disease
EF 2017-18 · 2018-01-02
Résumé
KalGene and its NRC partners have identified a novel biological agent against amyloid-beta for Alzheimer’s disease. The IRAP project will support the late-stage development of the drug candidate..
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Montreal|Montréal, Quebec, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
830005526
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Additional Information
This agreement has been amended 1 time(s). The total amended value is 68,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de 68 000 dollars.
Agreement End Date
2019-03-31
Agreement Number
899107
Agreement Start Date
2018-01-02
Agreement Title
Development of a Biological Therapeutic Drug to Reverse Alzheimer's Disease
Agreement Title (French)
Développement d'un médicament thérapeutique biologique pour inverser la maladie d'Alzheimer
Agreement Type
Contribution
Agreement Value
$350,000.00
Amendment Date
2018-12-14
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
KalGene and its NRC partners have identified a novel biological agent against amyloid-beta for Alzheimer’s disease. The IRAP project will support the late-stage development of the drug candidate..
Description (French)
Développement d'un médicament thérapeutique biologique pour inverser la maladie d'Alzheimer
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Mount Royal
Federal Riding (French)
Mont-Royal
Federal Riding Number
24052
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
830005526
Recipient City
Montreal|Montréal
Recipient Country
CA
Recipient Legal Name
Kalgene Pharmaceuticals Inc.
Recipient Postal Code
H4P 2R2
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2018-2019-Q3-899107
